Corcept Therapeutics
79
7
10
59
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
11.4%
9 terminated/withdrawn out of 79 trials
86.8%
+0.3% vs industry average
19%
15 trials in Phase 3/4
25%
15 of 59 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (79)
Evaluating the Pharmacokinetics and Safety of Miricorilant
Role: lead
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
Role: lead
A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
Role: lead
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
Role: lead
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Role: lead
Study Evaluating the Bioavailability of Miricorilant With Optional Food Effect Assessment in Healthy Adult Subjects
Role: lead
Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer
Role: collaborator
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
Role: lead
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
Role: lead
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
Role: collaborator
Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM)
Role: lead
Evaluation of Miricorilant on Liver Fat in Patients With MASLD
Role: lead
Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Role: lead
A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas
Role: lead
A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome
Role: lead
Impact of Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult Participants
Role: lead
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
Role: lead
Effects of Hepatic Impairment on the Pharmacokinetics of Dazucorilant
Role: lead
Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant
Role: lead
Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)
Role: lead